Eliminate or Reduce Urges, Cravings, or Symptoms of Withdrawal
The Ohio Opioid Technology Challenge is a three-phase prize competition that seeks to accelerate the development and deployment of innovative technology solutions that address the opioid crisis through addiction prevention and treatment, and overdose avoidance and response.
The Challenge Phase consists of four Challenge Topics that address specific unmet needs or concerns related to opioid use, abuse and exposure. This Topic seeks solutions that eliminate or reduce urges, cravings, or symptoms of withdrawal.
Opioids are highly addictive and create serious addictive responses within those using them. When an individual finishes a prescription, or when an addicted user seeks recovery, their initial side-effects can be serious. Withdrawal symptoms can include nausea, sleeplessness or restlessness, and agitation. Even individuals who have undergone addiction treatment still fight urges and cravings that can lead to relapse.
This Topic seeks long lasting solutions to better prevent an addictive response from the use of opioids by eliminating or reducing urges, or by better treating the symptoms of withdrawal.
About the Challenge
NineSigma, on behalf of the State of Ohio, seeks challenge responses which Eliminate or Reduce Urges, Cravings, or Symptoms of Withdrawal.
Responses should be solutions already in development, focused specifically on the Topic. Responses could include but are not limited to: pharmaceuticals, medical devices, or other technologies that reduce cravings and urges or symptoms of withdrawal and offer lasting effects over time.
The Challenge Phase will conclude by awarding up to twelve (12) $200,000 prizes across the four Topics. Prize Recipients of the Challenge Phase will be eligible to compete in the final, Product Phase of the Challenge with prizes of $1 million or more.
GENERAL EVALUATION CRITERIA FOR ALL CHALLENGE TOPICS:
Responses should consider:
How your approach aligns with Key Attributes for the Topic for which you are submitting an Entry
Technology maturity and time to market
For similar approaches, preference will be given to the one that is more mature and/or that has a shorter time to market
Potential for broad deployment or implementation
Size/scope of audience impacted (“market size”)
KEY ATTRIBUTES FOR TOPIC 2 PREVENT:
Your approach should:
Reduce urges, cravings, or other symptoms of withdrawal
Offer lasting effect/s over time
Not pose other significant health risks
Preferably be in a later stage of development
For a pharmaceutical, preferably at least be in human clinical trials
For a medical device, preferably have received 510 (k) clearance